
|Videos|August 4, 2020
ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD
Author(s)Alex Delaney-Gesing
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Advertisement
Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key takeaways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Atrophy Advisor: An online tool to inform GA treatment decisions
2
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
3
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5








































